TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04117009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 MG
Description: Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation
Description: Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation
Description: Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.
Study: NCT01688856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulator
Description: The 12-week treatment period consists of two components:~1. Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~2. Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulator
Description: The 12-week treatment period consists of two components:~1. Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~2. Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulator
Description: The 12-week treatment period consists of two components:~1. Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~2. Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes.
Study: NCT00253877

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complication rate
Description: All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.

Intervention type: OTHER
Group type: OTHER
Intervention: Complication rate
Description: All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
Study: NCT02592512

Intervention type: OTHER
Intervention: NIV-NAVA
Description: Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.

Intervention type: OTHER
Intervention: NIV-NAVA
Description: Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.

Intervention type: OTHER
Intervention: NIV-PS/PC
Description: Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.

Intervention type: OTHER
Intervention: NIV-PS/PC
Description: Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
Study: NCT00972777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin
Description: Besifloxacin 0.6% administered into the study eye two times a day for three days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo)
Description: Vehicle administered to the study eye two times a day for three days.
Study: NCT00654342

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraoperative injection (in vivo)
Description: Intraoperative injection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Postoperative injection (ex vivo)
Description: postoperative injection
Study: NCT06000020

Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy as performed as standard world wide. Division of the appendix with laparoscopic stapler.
Study: NCT03933774

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tretinoin 0.05% cream
Description: Stieva-A Cream 0.05%, 25g, GSK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% cream
Description: Stieva-A Cream 0.05%, 25g, GSK

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo cream
Description: Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
Study: NCT00803270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical Intervention
Description: Both oral urge incontinence medication and behavioral treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical
Description: Initial surgical (stress incontinence surgery) treatment approach.
Study: NCT04445181

Intervention type: DRUG
Intervention: The physician's prescription in routine clinical practice
Description: This is an Observational study that will not involve prescription of the drugs.
Study: NCT00541723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin)
Description: Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin)
Description: Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection at day 0, at 3 and 4 injection sites per eye.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
Study: NCT03628365

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB (beta-hydroxy beta-methylbutyrate)
Description: 1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HMB (beta-hydroxy beta-methylbutyrate)
Description: 1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
Study: NCT05767671

Intervention type: OTHER
Group type: OTHER
Intervention: Non-Bronchoscopic Mini Bronchoalveolar Lavage
Description: A minimally invasive technique frequently used in the ICU to obtain alveolar fluid samples from mechanically ventilated patients. The technique uses a commercially available telescoping catheter with a curved distal tip that allows the operator to direct the catheter into the right or left lung. The catheter is passed through an air-tight adapter on the distal end of the endotracheal tube and gently advanced to the desired lung until resistance is encountered. The inner catheter is then advanced until resistance is again encountered, signifying that the distal catheter tip is wedged. 20ml of sterile saline is instilled into the catheter followed by 5 ml of air, and the fluid aspirated. Two additional 20ml aliquots of sterile saline are injected and aspirated in a similar fashion. Specimens are pooled and on average provide a combined volume of 10ml.
Study: NCT03502954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-039
Description: ABY-039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-039
Description: ABY-039

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02832700

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein glycomacropeptide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04527120

Intervention type: OTHER
Group type: OTHER
Intervention: indigenously developed ultrasound phantom (IDUP)
Description: Ultrasound phantom model developed in the department of Emergency Medicine of Jubilee Mission Medical College, to train vascular access.

Intervention type: OTHER
Group type: OTHER
Intervention: indigenously developed ultrasound phantom (IDUP)
Description: Ultrasound phantom model developed in the department of Emergency Medicine of Jubilee Mission Medical College, to train vascular access.
Study: NCT02842892

Intervention type: OTHER
Group type: OTHER
Intervention: Tissue stiffness

Intervention type: OTHER
Group type: OTHER
Intervention: Tissue stiffness

Intervention type: OTHER
Group type: OTHER
Intervention: Tissue stiffness
Study: NCT03408782

Intervention type: PROCEDURE
Intervention: Insertion of drainage
Study: NCT03787225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0174-0833)
Description: Participants will receive NNC0174-0833 matched placebo subcutaneously.
Study: NCT02272049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129 Xenon
Description: During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
Study: NCT01670123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Real-Time Intervention for Stabilizing Mood
Description: Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Personalized Real-Time Intervention for Stabilizing Mood
Description: Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder
Study: NCT03351166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
Study: NCT00909454

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2000 IU Vitamin D3 daily supplement
Description: 2000 IU vitamin D3 supplement to be taken once daily over 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 400 IU Vitamin D3 supplement
Description: 400 IU Vitamin D3 supplement to be taken daily over 4 months
Study: NCT00639223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Yeast Rice
Description: Four 600mg capsules twice daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: One 20mg capsule twice daily for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification program
Description: Weekly sessions each lasting 3 1/2 hours for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Description: Weekly sessions each lasting 3 1/2 hours for 12 weeks
Study: NCT00521742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
Study: NCT03726762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBs at the end of the main meal + weight control program
Description: Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water at the end of the main meal+ weight control program
Description: Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
Study: NCT02921269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00984035

Intervention type: OTHER
Intervention: urine samples (biomarkers)
Description: Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.

Intervention type: OTHER
Intervention: blood samples (biomarkers)
Description: blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.

Intervention type: OTHER
Intervention: blood sample (DNA)
Description: Blood sample collected for DNA analysis at anytime while on-study.

Intervention type: OTHER
Intervention: blood sample (DNA)
Description: Blood sample collected for DNA analysis at anytime while on-study.
Study: NCT01475552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: Patients, who showed PRU \>270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Patients,who showed PRU \>270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.~Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd
Study: NCT01088100

Intervention type: GENETIC
Intervention: Genotyping
Description: Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples

Intervention type: GENETIC
Intervention: Genotyping
Description: Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
Study: NCT01419041

Intervention type: DRUG
Group type: OTHER
Intervention: crizotinib
Description: Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =\>90 mL/min)

Intervention type: DRUG
Group type: OTHER
Intervention: crizotinib
Description: Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr \<30 mL/min)
Study: NCT01920386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride/Acetaminophen Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride/Acetaminophen SR Tab.
Study: NCT04515069

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional technique of tooth preparation
Description: Depth cutter wheels of predetermined depths (Komet, Germany) were used to perform the preparation directly on the tooth structure.~Depth cuts were performed on the labial surface using depth cutter wheels (Komet, Germany) with radius of 0.3 mm and 0.5 mm which is directly related to the thickness of the laminate veneers in the cervical and incisal one thirds respectively. Then islands of tooth structure between depth orientation grooves were removed.~Proximal reduction:~The interproximal reduction was completed just labial to the contact areas using a round end tapered diamond stone (Mani, Japan), and polishing was performed using polishing strips (Sof-Lex, 3M ESPE, Seefeld, Germany).~Incisal reduction:~Vertical depth grooves were created. Then, the round end tapered diamond stone (Mani, Japan)was used to create 1.5 mm incisal butt joint preparation.~Then, finishing and polishing of tooth preparation was performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aesthetic preevaluative temporary technique for tooth preparation
Description: The data obtained from digital smile design was used for construction of the diagnostic wax-up. The wax-up was then be transferred to the mouth using a silicone index, creating the aesthetic pre-evaluative temporary (APT). The APT was tested esthetically and functionally. Once approved by the operator and the patient, tooth preparation was performed through the APT. Depth cuts were performed similar to those performed in the traditional preparation with the difference of being prepared on the aesthetic pre-evaluative temporary instead of directly on the dental structure. Using tapered stone with round end (Mani, Japan), islands of tooth structure between depth orientation grooves were removed.~Proximal reduction, Incisal reduction Finishing and polishing of tooth preparation were carried out using the same technique as in the Group T with the difference of being performed through the APT, resulting in minimal tooth preparation
Study: NCT02210377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tianjiu
Description: After randomization, patients in Tianjiu and placebo (non-Tianjiu) groups will receive 12 sessions of treatment over a 4-week treatment period.The format of the Tianjiu intervention will be the same as in the treatment group. Participants will be instructed to lie supine before their HD session, and then the bilateral KI1 and CV4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (non-Tianjiu)
Description: The format of the placebo (clay) intervention will be the same as in the treatment group.
Study: NCT01033253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health in Motion
Description: Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
Study: NCT02629471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: response time due to light flash pulses
Description: light flash pulses effect on response time to random targets appearance
Study: NCT03979560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Nutritional support in seven sessions spread over three months, combined with an adapted physical activity intervention (APA), also at a frequency of seven sessions spread over three months, or fourteen home sessions.
Study: NCT02216487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA-Irinotecan
Description: HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
Study: NCT03147079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Study: NCT01786239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.

Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone
Description: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 capsules
Description: The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.
Study: NCT01209312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus timing and dosing
Description: We will be altering the timing and dosages of the prescribed meal bolus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus timing and dosing
Description: We will be altering the timing and dosages of the prescribed meal bolus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus timing and dosing
Description: We will be altering the timing and dosages of the prescribed meal bolus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bolus timing and dosing
Description: We will be altering the timing and dosages of the prescribed meal bolus.
Study: NCT02400034

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voiding trial
Description: 1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voiding trial
Description: 1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy